

PERSONAL INFORMATION

Gwenaelle Veyrac

WORK EXPERIENCE

1990- Present

MD

hospital (France)

Pharmacologist Pharmacovigilance Spontaneous reporting systems and database

EDUCATION AND TRAINING

- Present

pharmacologist

biology institute (France)

ADDITIONAL INFORMATION

Expertise

16 Octobre 89 : These Doctorat en Medecine : Dysplasie renale, hepatique et pancreatique. A propos d'une observation.

1989-1993 : Remplacements en Medecine Generale

Juin 1992 : Certificat de Maitrise C2 (Pharmacologie Clinique)

Juin 1993 : Certificat de Maitrise C1 (Statistique, Informatique et modelisation de la maitrise de sciences biologiques et medicales).

Juin 1994 : Certificat de Maitrise C1 (Pharmacologie Generale)

Juillet 1994 : Maitrise de Sciences Biologiques et Medicales (Pharmacologie)

Mars 2003 : Concours National de Praticien Hospitalier Type II Medecine generale

29 10 90 : Nomination comme Attache au Centre de Pharmacovigilance de Nantes

01 11 92 : 1ere nomination triennale

01 01 96 : Nomination Attache en Premier - Attache avec 9 vacations hebdomadaires au Centre Regional de Pharmacovigilance de Nantes

01 01 03 : Nomination comme Praticien Attache au Centre Regional de Pharmacovigilance de Nantes

01 07 05 : Nomination a titre probatoire comme Praticien Hospitalier a temps partiel

01 07 06 : Nomination a titre permanent comme Praticien Hospitalier a temps partiel

20 04 07 : Nomination en qualite de Praticien Hospitalier a temps plein

01 01 10 : Suppleante du Professeur Pascale JOLLIET au sein du CRPV

15 04 19 : Nomination responsable du Centre Regional de Pharmacovigilance

Publications

Publications Internationales

1- P. JOLLIET, G. VEYRAC, M. BOURIN. First report of mirtazapine -induced arthralgie. Eur Psychiatry 2001 ; 16 : 1-3

2- O. LAMBERT, G. VEYRAC, C. ARMAND et al. A lamotrigine-induced neutropenia with an equivalent of positive reintroduction. Adv Drug React Toxicol Rev. 2002, 21 : 157-159

3- G. VEYRAC, P. JOLLIET. Urticaire medicamenteuse et imputabilite. Rev Fr Allergol Immunol Clin 2006; 46 : 283-7

4- C. VICTORRI-VIGNEAU, E.DAILLY, G.VEYRAC, P.JOLLIET. Evidence of zolpidem abuse and dependence : results of the French Center for Evaluation and Information on Pharmacodependance (CEIP) network survey. Br J Clin Pharmacol 2007; 64,2 : 198-209

5- P. JOLLIET, S. NION, G. ALLAIN-VEYRAC, L. TILLOY-FENART, D. VANUXEEM, V. BEREZOWSKI, R. CECHELLI. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using and in vitro

model of the Blood-Brain Barrier. *Pharmacol Res* 2007; 56 : 11-7

6- M. GERARDIN-MARAIS, C. VICTORRI-VIGNEAU, G. ALLAIN-VEYRAC, A. CHASLERIE, M. NICOLAS, N. SARRAF, J. PIVETTE, P. JOLLIET. Diuretic Drugs Use in the Elderly: Which Monitoring? *Eur J Clin Pharmacol* 2008; 64 : 433-7

7- C. CAILLET, G. DURRIEU, A. JACQUET and French Network of Pharmacovigilance Centres (G. VEYRAC). Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. *Eur J Clin Pharmacol* 2011; 67 : 649-651

8- G.ALLAIN-VEYRAC, A.LEBRETON, C.COLLONNIER, P.JOLLIET. First case of symmetrical drug-related intertriginous and flexural exanthema due to rivastigmine ? *Am J Clin Dermatol* 2011; 12,3 : 210-213

9- G. DURRIEU, C. CAILLET, I. LACROIX, A. JACQUET, A. FAUCHER, S. OUARET, A. SOMMET, M-C PERAULT-POCHAT, C. KREFT-JAIS, A. CASTOT, C. DAMASE-MICHEL, J-L. MONTASTRUC et le reseau francais des centres de pharmacovigilance (CPRV Nantes, G. VEYRAC) Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. *Therapie* 2011 ; 66, 6 : 527-54

10- A. PIPET, G. VEYRAC, F. WESSEL, P. JOLLIET, A. MAGNAN, P. DEMOLY and P.J. BOUSQUET. A statement on cefazolin immediate hypersensitivity : data from a large database, and focus on the cross-reactivities. *Clin Exp Allergy*. 2011 ; 41 : 1602-8

11- G. DURRIEU, A. PALMARO, L. POURCEL et al (G. VEYRAC pour CRPV Nantes). First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines : a comparison of reports submitted by patients and healthcare professionals. *Drug Saf* 2012, 35 ; 10 : 845-54

12- C. JOYAU, G. VEYRAC, V. DIXNEUF, P. JOLLIET. Anti tumor necrosis factor alpha therapy and increased risk of de novo psoriasis ; is it really a paradoxical side effect ? *Clin Expert Rheumatol* 2012 ; 30 : 700-6

13- F. CHAVANT, I. INGRAND, A.P. JONVILLE-BERA, C. PLAZANET, V. GRAS-CHAMPEL, L. LAGARCE, M. ZENUT, A. DISSON-DAUTRICHE, S. LOGEROT, M. AUFFRET, A. COUBRET-DUMAS, M.L. BRUEL, M. BOYER, M.A. BOS-THOMPSON, G. VEYRAC, P. CARLIER, M.N. BEYENS, S. LATES, C. DAMASE-MICHEL, A. CASTOT, C. KREFT-JAIS, M.C. PERAULT-POCHAT. The PREGVAXGRIP study : a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A (H1N1) v2009 influenza. *Drug Saf* 2013; 36 : 455-65

14- M. REITTER, N. PETITPAIN, C. LATARCHE, J. COTTIN, N. MASSY, P. DEMOLY, P. GILLET, P.M. MERTES, the French Network of Regional Pharmacovigilance centres (G. VEYRAC citee). Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. *Allergy* 2014, 69 ; 954-9

15- G. MOULIS, H. BAGHERI, L. SAILLER, AP. JONVILLE-BERA, E. WEBER, C. GUY, N. PETITPAIN, ML. LAROCHE, S. FAVRELIERE, J. BENE, B. BALDIN, L. VILLEVAL-FEDERICI, M. TEBACHER-ALT, V. BRES, G. VEYRAC, A. GRANDVUILLEMIN, C. MAUPRIVEZ, M. LAPEYRE-MESTRE, JL. MONTASTRUC, French Association of Pharmacovigilance Centers. Are adverse drug reaction patterns different between romoplostim and eltrombopag? 2009-2013 French Pharmacovigilance assessment. *Eur J Intern Med* 2014; 25 : 777-80

16- D. DARNIS, G. VEYRAC, P. JOLLIET. The special case of diclofenac. *Enliven Archive* 2014

17- L. GABORIAU, C. VICTORRI-VIGNEAU, M. GERARDIN, G. ALLAIN-VEYRAC, P. JOLLIET-EVIN, M. GRALL-BRONNEC. Aripiprazole : A new risk factor for pathological gambling? A report of 8 case reports. *Addict Behav* 2014; 39: 562-5

18- S. HENNI, F. DELAMARRE-DAMIER, A. SONNIC, G. FEINARD, G. VEYRAC, JF; PUJOL, L. DE DECKER, G. BERRUT, S. PLESSARD.

NEURODEM : assessment of the iatrogenic alert indicator for nursing home patients with Alzheimer's of Alzheimer-like disease. *Aging Clin Exp Res*. 2015 ; 2015 Dec 6. [Epub ahead of print]

19- D. DARNIS, J. MAHE, B. VRIGNAUD, C. GRAS-LE GUEN, G.VEYRAC, P.JOLLIET. A report of adverse drug reactions in Pediatric Emergency Medicine. *Annals of Pharmacotherapy* 2015, Dec;49(12):1298-304

20- J. MAHE, D. DARNIS, G.VEYRAC, P.JOLLIET. Reply : Adverse Drug Reactions in Pediatric Emergency Medicine *Ann Pharmacother*. 2016 ;50(4): 332-333

21- LE TURNIER P, BOUTOILLE D, JOYAU C, VEYRAC G, ASSERAY N. Bacterial infections and NSAIDs exposure? Seek septic complications. *European Journal of internal medicine*. 2017.

- 22- DENIS PREVOT M, THILLARD EM, WALTHER J, VEYRAC G, LAROCHE ML, GAUTIER S, AUFFRET M. Pristinamycin-induced arthralgia and myalgia: Analysis of the French Pharmacovigilance Database. *Med Mal Infect.* 2017 Oct 28. pii: S0399-077X(16)30720-X. doi: 10.1016/j.medmal.2017.09.014. [Epub ahead of print]2017.
- 23- LEBRUN-VIGNES B, GUY C, JEAN-PASTOR MJ, GRAS-CHAMPEL V, ZENUT M and The French Network of Regional Centres of Pharmacovigilance and the French Investigators for Adverse Skin Reactions to Drugss acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. *Br J Clin Pharmacol* 2018 Feb;84(2):331-338. doi: 10.1111/bcp.13445. Epub 2017 Nov 10.
- 24- TOURILLON C, MAHE J, BARON A, LAMBERT A, YELEHE-OKOUMA M, VEYRAC G, JOLLIET P. Immediate-type hypersensitivity cross-reactions to proton pump inhibitors: A descriptive study of data from the French national pharmacovigilance database *Int Arch Allergy Immunol* 2018
- 25- PETITPAIN N, ARGOULLON L, MASMOUDI K, FEDRIZZI S, COTTIN J, LATARCHE C, MERTES P, GILLET P, FRENCH NETWORK OF REGIONAL PHARMACOVIGILANCE CENTRES (G VEYRAC COLLAB) (2018) Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012. *Allergy*, 73(11): 2224-33.
- 26-Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, Gouraud A, Mahe J, Lesclous P. Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated to fatal anaphylaxis and Clostridium difficile infections in France. *Med Oral Patol Oral Cir Bucal.* 2019 May 1;24 (3):e296-304.
- 27- Hillaire-Buys D, Mousset M, Allouchery M, Azzouz B, Babin M, Bellet F, Bene J, Default A, Durrieu G, Geniaux H, Grandvullemin A, Gras-Champel V, Jantzen H, Lambert A, Lepelley M, Massy N, Petitpain N, Rocher F, Sanchez-Pena P, Sassier M, Simon C, Triquet L, Valnet-Rabier MB, Veyrac G, Faillie JL, Zenut MC. Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population. *Therapie.* 2019 Oct 28. PMID: 31732241.
- 28- Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms (DRESS) may occur within two weeks of drug exposure: a retrospective study. *J Am Acad Dermatol.* 2019 Sep 25. PMID: 31562941.
- 29- Gregoire M, Le Turnier P, Gaborit BJ, Veyrac G, Lecomte R, Boutoille D, Canet E, Imbert BM, Bellouard R, Raffi F. Lopinavir pharmacokinetics in COVID-19 patients [published online ahead of print, 2020 May 22]. *J Antimicrob Chemother.*
- 30-Gouverneur A, Sanchez-Pena P, Veyrac G, Salem JE, Begaud B, Bezin J. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis. *Cardiovasc Drugs Ther.* 2021 Aug 26. doi: 10.1007/s10557-021-07242-7. Online ahead of print. PMID: 34436707
- Baudot J, Soeiro T, Tambon M, Navarro N, Veyrac G, Mezaache S, Micallef J. Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market. *Fundam Clin Pharmacol.* 2022 Jun;36(3):572-581. doi: 10.1111/fcp.12745. Epub 2021 Dec 23. PMID: 34907579.

Publications Nationales

- 1- P. NETTER, Ph TRECHOT, G. ALLAIN et al. Le medecin francais face a un effet inattendu. *Communications partenaires sante*, 1992, numero special.
- 2- A.CHIFFOLEAU, G. VEYRAC, S. BAUDOT et al. "Bilan de 2 annees de suivi des questions "Medicaments - Grossesse" au CRPV de Nantes". *Therapie* 1995 ; 50 : 429-438.
- 3- G. VEYRAC, A. CHIFFOLEAU, C. BAILLY et al. Hypertrichose chez un nourrisson d'une mere traitee par Minoxidil topique pendant les 6 derniers mois de grossesse. *Therapie* 1995 ; 50 : 463-484.
- 4- S. BEAUDOUIN, J. JACQUEMIN, A. CHIFFOLEAU, G. VEYRAC et al. Choc anaphylactique apres une injection de morphine. *Therapie* 1996 ; 51 : 191-196.
- 5- C. LAROUSSE, A. CHIFFOLEAU, G. VEYRAC. Pharmacovigilance, Obligation legale ou obligation morale ? *Therapeutiques*, avril 1999 ; 41.
- 6- V. BRICARD-PACAUD, A. CHIFFOLEAU, G. VEYRAC et al. Frequency and cost evaluation of adverse drug reactions in a department of general medicine. *Therapie* 1999 ; 54 : 282.
- 7- N. ROUX-JEGOU, D. EL KOURI, JF CESARI, G. VEYRAC et al. Impact of iatrogenic effects on hospitalization in a department of general medicine : involvement of different health professionals.

Poster. Therapie 1999 ; 54 : 289.

- 8- G. VEYRAC, A. CHIFFOLEAU, L. CELLERIN et al. Latanoprost (XALATAN*) et effet systemique respiratoire ? A propos d'un cas. Therapie 1999 ; 54 : 494-496.
- 9- C. LAROUSSE, A. CHIFFOLEAU, G. VEYRAC et al. Conditionnement : carton rouge. La Revue Prescrire 1999 ; 19 : 715.
- 10- C. LAROUSSE, G. VEYRAC. Les inhibiteurs de COX-1 et COX-2, donnees cliniques = Quelles alertes possibles en Pharmacovigilance ? Therapie 2000 ; 55 : 21-28.
- 11- A.CHIFFOLEAU, D. YATIM, F. GARREC, G. VEYRAC et al. Warning ! a buflomedil may hide another ! Therapie 2000 ; 55 : 221-223.
- 12- N. ROUX-JEGOU, G. VEYRAC, R. CLEMENT et al. Methotrexate a faibles doses et supplementation en folates. La Revue du Praticien - Medecine Generale 2000 ; 14 : 187-190.
- 13- G. VEYRAC, B. GUILLON, N. THAJTE et al. Cerebral vasculitis and hemorrhage associated with phenylpropanolamine. Therapie 2000 ; 55 : 410.
- 14- A.CHIFFOLEAU, G. VEYRAC, V. ARGAIZ et al. First report of a possible interaction between acenocoumarol and topical treatment CYCLO 3(R). Therapie 2000 ; 55 : 411.
- 15- G. VEYRAC, V. BRACHET, S. ROCHER et al. Mirtazapine (NORSET(R)) and arthralgie. Therapie 2000 ; 55 : 422.
- 16- G. VEYRAC, V. BRACHET, S. ROCHER et al. Arthralgies associees a la prise de Mirtazapine. Therapie 2000 ; 55 : 652-655.
- 17- G. VEYRAC, H. HUGUENIN, B. GUILLON et al. Hemorragies cerebromeningees et angiopathie cerebrale aigue associees a la prise de phenylpropanolamine. Un nouveau cas. Therapie 2001, 56 : 323-327.
- 18- A.CHIFFOLEAU, H. HUGUENIN, G. VEYRAC et al. Interaction entre melilot et acenocoumarol ? (melilot-ruscus aculeatus). Therapie 2001, 56 : 321-322.
- 19- G. VEYRAC, M. PAULIN, B. MILPIED et al. Bilan de l'enquete nationale sur les effets indesirables cutanes du ketoprofene gel enregistres entre le 01/09/1996 et le 31/08/2000. Therapie 2002, 57 : 55-64.
- 20- G. VEYRAC, A. CHIFFOLEAU, M. BOURIN et al. Photosensibilite exogene liee a la prise d'AINS sous forme topique. La Lettre du pharmacologue 2002, 16 : 161-166.
- 21- A.CHIFFOLEAU, G. VEYRAC, C. BRUNET-FRANCOIS et al. Recueil systematique des effets indesirables des medicaments du VIH : Bilan de 18 mois de collaboration du CISIH et du CRPV. La Lettre du Pharmacologue 2002, 16, 123-129.
- 22- A.ANGLES, H. BAGHERI, J.L. MONTASTRUC, J.F. MAGNAVAL + RESEAU DES CENTRES DE PHARMACOVIGILANCE. Pharmacovigilance des medicaments antipaludiques. Analyse de la notification spontanee en France (1996-2000). La Presse Medicale 2003, 32 : 106-13.
- 23- G. VEYRAC, G. MARCADE, A. CHIFFOLEAU et al. Caracteristiques du syndrome d'hypersensibilite a la lamotrigine : revue a partir d'un cas observe au CRPV de Nantes. Therapie 2002, 57 : 289-296.
- 24- S. BOURLON, G. VEYRAC, C.ARMAND et al. Rhabdomyolyse sous rabeprazole (PARIET(R)), un inhibiteur de la pompe a protons. Therapie 2003, 57 ; 6 : 597-600.
- 25- A.CHIFFOLEAU, J.N. TROCHU, G. VEYRAC et al. Rhabdomyolyse liee a l'ajout du verapamil a un traitement par simvastatine et ciclosporine chez un patient transplante cardiaque. Therapie 2003 ; 58 : 168-170.
- 26- A.CHIFFOLEAU, G. VEYRAC, G. MIREMONT et al. Tramadol et anticoagulants oraux : Quel type d'interaction ? Therapie 2003 ; 58 : 471-474.
- 27- CHIFFOLEAU, .D. DRUI, G. VEYRAC, J.M. CHALIGNY, B. MILPIED, P. JOLLIET. Urticaire cholinergique revelee par les -bloquants. A propos d'un cas et de sa prise en charge therapeutique. Therapie 2005; 60 : 593-5.
- 28- G. VEYRAC, L. CELLERIN, P. JOLLIET. Premier cas de pneumopathie interstitielle rapporte sous atorvastatine (TAHOR(R)) : Synthese des cas publies sous statines. Therapie 2006; 61 : 57-67.
- 29- M. GERARDIN-MARAIS, G. ALLAIN-VEYRAC, I. DANNER, P. JOLLIET. Lithiase biliaire et cholecystite au voriconazole (V-FEND(R)) - A propos de 3 cas nantais en 2004. Therapie 2006; 61 : 367-9.
- 30- VICTORRI-VIGNEAU, M. MARAIS, G. VEYRAC, A. CHASLERIE, J. PIVETTE, P. JOLLIET. Reactivite et communication des decisions de pharmacovigilance des autorites de sante vers les professionnels de sante : exemples du pergolide et du celecoxib. Therapie 2007; 62 : 513-7.
- 31- G. VEYRAC, A. LEBRETON, P. JOLLIET. Osteonecroses de la machoire associees a la prise

de biphosphonates. La Lettre du Pharmacologue 2009; 23 ,2 : 41-7.

32- J-L. MONTASTRUC et coll (G. VEYRAC pour CRPV Nantes). Pharmacovigilance study of influenza A H1N1 vaccination during the 2009-2010 season in France. Bull Acad Natl Med 2011; 195, 6 : 1309-17.

33- A.NEEL, M. SEVIN, E. AUFRAY-CALVIER, G. VEYRAC, B. GUILLON, M. HAMIDOU. Medicaments vasoconstricteurs et syndrome de vasoconstriction cerebrale reversible : a propos de 22 cas. La Revue de Medecine Interne 2012; CO029 : A42.

34- VICTORRI-VIGNEAU C, PAILLE C, JOYAU C, VEYRAC G, COSSET C, LE PELLETIER A, JOLLIET P, NIZARD J, KUHN E. MEOPA use practices in a university hospital: Which conformity? Therapie Dec;72(6):659-663. doi: 10.1016/j.therap.2017.04.003. Epub 2017 May 26.. 2017

35- BERTHELOT JM, VEYRAC G. Arthralgies et arthrites d'origine medicamenteuses, rares ou emergentes. Revue du rhumatisme 2018.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)